# Insamo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/insamo

- Industry: Biotechnology
- Headquarters: Berkeley, US
- Website: www.insamo.com/
- Total disclosed funding: $9.5M
- Latest round: Seed (Mar 8, 2023)
- Investors on record: 7

## About

Insamo, Inc. is a US-based company dedicated to automating the design, synthesis, and testing of drug candidates, focusing on innovative solutions that enhance drug discovery processes for pharmaceutical and research institutions.Founded by Timothy Craven and Toby Passioura, Insamo, Inc. is headquartered in Berkeley, US. The company specifically targets the development of orally available cyclic peptides, having raised USD 9.525 mn in Seed funding in March 2023 from investors including Playground Global and VenBio, marking its first deal. The total amount raised to date stands at USD 9.525 mn with a current valuation of USD 23.354 mn.Insamo specializes in an innovative platform that automates the design, synthesis, and testing of drug candidates at an unprecedented scale. Its core offerings leverage a unique approach that integrates machine learning with a vast database of proprietary experimental data, enabling the rapid iteration of design cycles across a wide chemical space. The primary focus is on the discovery of membrane-permeable and orally available cyclic peptides, which addresses critical needs in drug delivery and bioavailability. Insamo's solutions are tailored for pharmaceutical companies and research institutions, thereby serving a diverse client base that spans North America, Europe, and parts of Asia. By providing tools for drug design, Insamo positions itself as a key player in advancing therapeutic development across these geographical markets.Insamo's revenue model is centered around strategic partnerships and collaborations with pharmaceutical companies and research organizations. These transactions typically involve service agreements that may include project-based fees for specific drug development initiatives, as well as ongoing partnerships for software licenses and access to the platform's capabilities. Clients engage in B2B transactions, utilizing Insamo's technology to expedite their drug discovery processes. The financial arrangements vary depending on the scope of collaboration, with potential pricing structures based on the complexity and duration of projects. Insamo's flagship services enhance the drug design process, forming the basis of its revenue-generating activities.In March 2023, Insamo, Inc. raised USD 9.52 mn in Seed funding, intended to support the development of new products and enhance existing platform capabilities. The company aims to enter additional markets in Europe and Asia by 2024, expanding its user base and fostering new partnerships. The funding will enable Insamo to accelerate its R&D efforts, thereby facilitating the launch of new drug design tools within the coming year.

## Funding rounds

- Seed, Mar 8, 2023, $9.5M — VenBio, Playground Global, LLC, Civilization Ventures, Sahsen Foundation, MRL Ventures Fund, Axial VC, BEVC

## Investors

- VenBio (https://capitalatlas.ai/funds/venbio) — Seed
- Playground Global, LLC — Seed
- Civilization Ventures (https://capitalatlas.ai/funds/civilization-ventures) — Seed
- Sahsen Foundation — Seed
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Seed
- Axial VC (https://capitalatlas.ai/funds/axial-vc) — Seed
- BEVC (https://capitalatlas.ai/funds/bevc) — Seed